Table 1.

Inhibitors of angiogenesis currently used in clinical practice [11].

Angiogenic inhibitor	Target	Current clinical use
Bevacizumab	VEGF	First approved by the United States Food and Drug Administration (FDA) in February 2004 for patients with metastatic colorectal cancer. Nowadays it is used for other malignancies, including breast cancer.
Sorafenib	VEGFR2 and 3, PDGFR-β, FLT3 and KIT	Renal cell carcinoma, Hepatocellular carcinoma,
Sunitinib	PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET	Renal cell carcinoma, Gastrointestinal stromal tumors
Thalidomide	fibroblast growth factor-2 (FGF-2) and tyrosine kinase FGF receptors	Myeloma
Aflibercept (Soluble VEGF receptors)	VEGF-A, VEGF-B, and placental growth factor (PlGF)	Metastatic nonsmall cell lung cancer, Prostate cancer
Vascular disrupting agents (VDAs)	The biological VDAs combine an endothelium-targeting molecule with a toxin or pro-coagulant	Anaplastic thyroid cancer